Granite Point Capital Management’s Eterna Therapeutics ERNA Stock Holding History

Granite Point Capital Management’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1	Closed	-$160K	–	92
2015 Q2	$160K	Hold	1	–	–	0.05%	94
2015 Q1	$378K	Hold	1	–	–	0.14%	82
2014 Q4	$396K	Hold	1	–	–	0.19%	69
2014 Q3	$366K	Hold	1	–	–	0.18%	72
2014 Q2	$588K	Hold	1	–	–	0.4%	56
2014 Q1	$729K	Sell	1 -1	-50%	-$490K	0.52%	60
2013 Q4	$630K	Buy	+2	New	+$874K	0.1%	80

Other funds holding ERNA

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granite Point Capital Management's ERNA Position: Q3 2015 in Review

Granite Point Capital Management sold out of Eterna Therapeutics (ERNA) in Q3 2015, closing a stake of 1 share — an estimated $160K sold.

Granite Point Capital Management first reported a position in ERNA in Q4 2013 and held it in 7 quarters. The position peaked at $729K in Q1 2014. 6 funds tracked by Wall St. Rank hold ERNA as of Q3 2015.

Granite Point Capital Management reported no remaining Eterna Therapeutics position as of Q3 2015 after selling out during the quarter.
Granite Point Capital Management sold 1 Eterna Therapeutics share in Q3 2015, an estimated $160K.
Granite Point Capital Management first reported a position in Eterna Therapeutics in Q4 2013 and held it in 7 quarters.
Granite Point Capital Management's Eterna Therapeutics position peaked at $729K in Q1 2014.
6 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2015.

Based on Granite Point Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.